Abstract

3. The leucite glass-ceramic is prepared by subjecting the glass components to a nucleation heat treatment, followed by a growth heat treatment. The leucite glass-ceramic may be used in the fabrication of a Dental restoration using various processes, and may be used in the construction of Dental restorations such as ceramic Dental inlays, crowns, veneers, bridges, veneering materials for zirconium oxide restoration substrates, alumina oxide restoration substrates, or metal restoration substrates.

IPC Classes  ?

• C03C 10/10 - Alkali metal aluminosilicate crystalline phase
• A61K 6/02 - Use of preparations for artificial teeth, for filling or for capping teeth
• C03C 10/00 - Devitrified glass ceramics, i.e. glass ceramics having a crystalline phase dispersed in a glassy phase and constituting at least 50% by weight of the total composition
• C03B 32/02 - Thermal crystallisation, e.g. for crystallising glass bodies into glass-ceramic articles
• C03C 3/087 - Glass compositions containing silica with 40% to 90% silica by weight containing aluminium oxide or an iron compound containing an oxide of a divalent metal containing calcium oxide, e.g. common sheet or container glass
• C03C 3/091 - Glass compositions containing silica with 40% to 90% silica by weight containing boron containing aluminium
• C03C 4/00 - Compositions for glass with special properties

Abstract

A leucite glass-ceramic is prepared from a glass comprising : about 66.8 to about 71.9 mol % of SiO2, about 8.5 to about 10.6 mol % of Al2O3, about 9.5 to about 12.8 mol % of K2O, about 0.5 to about 4.0 mol % of CaO, about 0 to about 3.0 mol % of TiO2, about 1.8 to about 4.0 mol % of Na2O, about 0.1 to about 6.0 mol % of Li2O, about 0 to about 1.0 mol % of MgO, about 0 to about 3.0 mol % of Nb2O5, and about 0 to about 3.0 mol % of B2O3. The leucite glass-ceramic is prepared by subjecting the glass components to a nucleation heat treatment, followed by a growth heat treatment. The leucite glass-ceramic may be used in the fabrication of a Dental restoration using various processes, and may be used in the construction of Dental restorations such as ceramic Dental inlays, crowns, veneers, bridges, veneering materials for zirconium oxide restoration substrates, alumina oxide restoration substrates, or metal restoration substrates.

IPC Classes  ?

• C03C 3/087 - Glass compositions containing silica with 40% to 90% silica by weight containing aluminium oxide or an iron compound containing an oxide of a divalent metal containing calcium oxide, e.g. common sheet or container glass
• C03C 3/091 - Glass compositions containing silica with 40% to 90% silica by weight containing boron containing aluminium
• C03C 4/00 - Compositions for glass with special properties
• C03C 10/00 - Devitrified glass ceramics, i.e. glass ceramics having a crystalline phase dispersed in a glassy phase and constituting at least 50% by weight of the total composition

Abstract

A chlorine-containing silicate glass comprising SiO2, at least 0.5 mole percent metal chloride and at least 10 mole percent of MgO, SrO, BaO, and CaO combined.

IPC Classes  ?

• A61C 3/025 - Instruments acting like a sandblast machine, e.g. for cleaning, polishing or cutting teeth
• A61L 27/42 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having an inorganic matrix
• A61K 8/20 - HalogensCompounds thereof
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses
• B24C 11/00 - Selection of abrasive materials for abrasive blasts
• C03C 1/00 - Ingredients generally applicable to manufacture of glasses, glazes or vitreous enamels
• C03C 3/062 - Glass compositions containing silica with less than 40% silica by weight
• C03C 3/11 - Glass compositions containing silica with 40% to 90% silica by weight containing halogen or nitrogen
• C03C 3/112 - Glass compositions containing silica with 40% to 90% silica by weight containing halogen or nitrogen containing fluorine
• C03C 4/12 - Compositions for glass with special properties for luminescent glassCompositions for glass with special properties for fluorescent glass
• C03C 10/00 - Devitrified glass ceramics, i.e. glass ceramics having a crystalline phase dispersed in a glassy phase and constituting at least 50% by weight of the total composition
• C03C 10/16 - Halogen-containing crystalline phase
• C03C 12/00 - Powdered glassBead compositions
• C09K 11/57 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing manganese or rhenium
• C03C 4/00 - Compositions for glass with special properties

Abstract

A bioactive glass composition comprising one or more glasses comprising Si02, P205 and a fluoride, the Si02 content being less than 40 mole %, the P205 content being at least 4 mole %, and the fluoride content being greater than 1 mole %. The bioactive glass or glass-ceramic can be used in a number of medical applications, including dental applications such as toothpaste.

IPC Classes  ?

• A61K 33/42 - PhosphorusCompounds thereof
• A61K 8/25 - SiliconCompounds thereof
• A61K 33/16 - Fluorine compounds
• A61K 8/21 - FluoridesDerivatives thereof
• A61L 27/10 - Ceramics or glasses
• A61L 27/12 - Phosphorus-containing materials, e.g. apatite
• A61K 8/27 - ZincCompounds thereof
• C03C 3/062 - Glass compositions containing silica with less than 40% silica by weight
• C03C 4/00 - Compositions for glass with special properties
• C03C 10/16 - Halogen-containing crystalline phase
• A61K 8/19 - Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
• A61K 8/24 - PhosphorusCompounds thereof
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 33/08 - OxidesHydroxides
• A61K 33/30 - ZincCompounds thereof

Abstract

A composition for making a cement or an implant, the composition comprising a silicate glass and at least one compound selected from the group consisting of a calcium phosphate salt, a strontium phosphate salt and a phosphate glass.

IPC Classes  ?

• C04B 12/02 - Phosphate cements

Abstract

The present invention provides a polypeptide having an amino acid sequence based on the sequence shown as SEQ ID No. 1 but comprising one or more mutations compared that sequence, whose expression in vivo is associated with tylosis and/or predisposition to develop cancer. The invention also provides a nucleic acid sequence capable of encoding such a polypeptide; a screening method for determining whether a compound may be useful in the treatment of cancer or inflammatory conditions; and a method for diagnosing cancer in a subject, based on the expression of such a polypeptide.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Hence, the invention relates to a method for diagnosis and/or prognosis of cancer, comprising the steps of analyzing in a sample of a subject the DNA methylation status of a genomic region of at least one member of the group of, (i) SFN according to SEQ ID NO. 1, (ii) SLIT2 according to SEQ ID NO. 2, (iii) SERPINB5 according to SEQ ID NO. 3; and (iv) TWIST 1 according to SEQ ID NO 4; wherein, if (i) SFN shows a methylation cut off value of above 80 % and/or, (ii) SLIT2 shows a methylation cut-off value of above 45 % and/or, (iii) SERPBINB5 shows a methylation cut-off value of above 70 %, and/or (iv) TWIST 1 shows a methylation level below 15 % the sample is categorized as a sample from a patient with cancer and/of a poor prognosis.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention provides an antigen binding polypeptide which specifically targets the synovial microvasculaturc of arthritis patients and comprises one or more complementarity determining regions (CDRs) selected from the group consisting of SEQ ID NOs 1 to 4. The present invention also relates to the use of such antigen binding polypeptides and conjugates thereof for use in the diagnosis and treatment of arthritis.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

Provided are methods for inducing platelet aggregation in a subject. The methods comprise administering to the subject a composition comprising IL-17 and/or a fragment or variant thereof. Also provided are compositions comprising IL-17 and/or a fragment or variant thereof for use in inducing platelet aggregation in a subject and compositions comprising (i) IL-17 and/or a fragment or variant thereof, and (ii) one or more haemostatic agents.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
• C07K 14/54 - Interleukins [IL]
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents

Abstract

Provided are methods for diagnosing cancer in a patient or for identifying a patient at risk of developing cancer. The methods comprise determining the amount of five or more biomarkers selected from HOXA7, AURKA, NEK2, FOXM1B, CCNB1, CEP55, CENPA, DNMT3B, DNMT1, HELLS, MAPK8, BMI1, ITGB1, IVL and CTNNB1 in a sample obtained from a patient and comparing the amount of the determined biomarkers in the sample from the patient to the amount of the biomarkers in or of a normal control. A difference in the amount of the biomarkers in the sample from the patient compared to the amount of the biomarkers in or of the normal control is associated with the presence of cancer or is associated with a risk of developing cancer. Also provided are methods for analysing the differential expression of biomarkers between samples obtained from a patient suffering from or suspected of suffering from cancer and samples obtained from or of a normal control, the method comprising analysing the differential expression using an algorithm. Further provided are kits for use in the methods.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

A bioactive glass composition comprising one or more glasses comprising Si02, P205 and a fluoride, the Si02 content being less than 40 mole %, the P205 content being at least 4 mole %, and the fluoride content being greater than 1 mole %. The bioactive glass or glass - ceramic can be used in a number of medical applications, including dental applications such as toothpaste.

IPC Classes  ?

• C03C 3/062 - Glass compositions containing silica with less than 40% silica by weight
• C03C 4/00 - Compositions for glass with special properties
• C03C 10/16 - Halogen-containing crystalline phase
• A61K 8/25 - SiliconCompounds thereof
• A61K 8/27 - ZincCompounds thereof
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses
• G01N 33/15 - Medicinal preparations

Abstract

Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C12N 15/62 - DNA sequences coding for fusion proteins
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper

Abstract

The present invention relates to compounds of the formula (I) wherein R1,R2, R3, R4, R5 and R6, X and n are as defined herein. Preferred compounds are inositol phosphate derivatives wherein R1 is a substituted or unsubstituted phenyl and at least one of R2, R3, R4, R5 and R6 is PO32- Alternative compounds are inositol phosphate derivatives of the formula (I) wherein R1 is a fiuorophore moiety The compounds are useful alone or in combination with known therapeutic agents for the treatment of diseases, especially cancer.

IPC Classes  ?

• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• C07F 9/117 - Esters of phosphoric acids with cycloaliphatic alcohols
• A61P 35/00 - Antineoplastic agents

Abstract

Apparatus for dispensing a powder, comprises a dispensing nozzle having an upper portion for containing a quantity of the powder, having a minimum internal horizontal dimension of 5mm, and a dispensing orifice below the upper portion, with a maximum internal horizontal dimension of from 200μm to 3mm. An internal passage leading from the said upper portion to the dispensing orifice tapers in a linear manner from its upper end to its lower end. The apparatus includes a transducer for applying vibrational pulses to the dispensing nozzle, to dispense doses of powder from the orifice. Vibrational pulses are controlled to control flow of powder through the nozzle.

IPC Classes  ?

• G01F 13/00 - Apparatus for measuring by volume and delivering fluids or fluent solid materials, not provided for in the preceding groups
• A47F 1/03 - Dispensing means
• B65B 37/04 - Supplying or feeding fluent-solid, plastic, or liquid material, or loose masses of small articles, to be packaged by vibratory feeders

Abstract

A method of monitoring the level of performance of a software application running on a network-attached computing device, comprises monitoring information exchange at least one station on the network; measuring at least two performance indicator metrics, such as delay, jitter, loss, response time, throughput, goodput, and object size; and deriving an indicator parameter, from a non-linear combination of the indicator metrics. A transformation may be applied to each indicator metric to obtaining a corresponding derived value, and the derived values then additively combined, to obtain the said indicator parameter. The transformation has a first region in which the derived value depends relatively weakly on the corresponding metric, and a second region, in which the derived value depends relatively strongly on the corresponding metric. A score value may be entered by a user, indicative of the user's perception of the performance of the software application, and compared with the derived indicator parameter. The calculation used to derive the indicator parameter may be varied, in dependence on the user-entered score. Diagnostic traces may be triggered in dependence on the derived indicator parameter. Values of the indicator parameter and associated trace data may be collected in a database and collated to diagnose and/or predict problems in the said computer system.

IPC Classes  ?

• G06F 11/34 - Recording or statistical evaluation of computer activity, e.g. of down time, of input/output operation
• H04L 12/26 - Monitoring arrangements; Testing arrangements

Abstract

A method for preventing or treating an NF-kappaB mediated disorder, such as an inflammatory disorder, an autoimmune disorder, or cancer, in a subject suffering from or at risk of suffering from an NF-kappaB mediated disorder is disclosed, wherein the method comprising administering to the subject an effective amount of a protein comprising an amino acid sequence comprising SEQ ID NO:1, or a fragment or variant thereof.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides isoquinoline, tetrahydroisoquinoline and tetrahydropyridopyrimidine compounds that induce cell death by apoptosis and uses of the compounds in medicine, expecially their use for treating cancer and other diseases.

IPC Classes  ?

• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07D 217/00 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
• C07D 217/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 471/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed system contains two hetero rings
• A61P 35/00 - Antineoplastic agents

Abstract

An audio navigation device comprising an input means for inputting two or more audio pieces into the navigation device; a spatialization means for allocating a position in the form of a unique spatial co-ordinate to each audio piece and arranging the audio pieces in a multi-dimensional arrangement; a generating means for generating a binaural audio output (3) for each audio piece, wherein the audio output (3) simulates sounds that would be made by one or more physical sources located at the given position of each audio piece; an output means for simultaneously outputting multiple audio pieces as binaural audio output (3) to a user (5); a navigation means (1) for enabling a user (5) to navigate around the audio outputs (3) in the multi-dimensional arrangement; a selection means (A) for allowing a user (5) to select a single audio output (3).

IPC Classes  ?

• H04S 7/00 - Indicating arrangementsControl arrangements, e.g. balance control

Abstract

The invention provides novel healthy kidney biomarkers useful in the monitoring of renal function and in the prognosis and diagnosis of renal dysfunctions, especially those related to graft rejection. The invention further relates to methods for aiding in the evaluation, and design of personalized therapies in transplantation nephrology.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The use of liquid formulations in the preparation of a medicament for the prevention and treatment of oral, gastric and digestive infections and in particular for the prevention of ventilator associated pneumonia as well as liquid enteral and parenteral tube feeding compositions. The feeding compositions are suitable for use in the prevention of ventilator associated pneumonia.

IPC Classes  ?

• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The invention provides methods and materials related to a gene expression-
based survival predictor for diffuse
large B cell lymphoma (DLBCL) patients.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention provides methods and materials related to a gene expression-based survival predictor for diffuse large B cell lymphoma (DLBCL) patients.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

A feedback-prevention method for a system with a signal processor comprising the steps of inputting at least one reference signal (9); calculating a spectral model (11) of the system according to the or each reference signal; generating a preventative gain compensation factor (12) according to the spectral model of the system; applying the preventative gain compensation factor (16) to the input or output of the signal processor (2); and outputting a gain-compensated audio output (3).

IPC Classes  ?

• H04R 3/02 - Circuits for transducers for preventing acoustic reaction

Abstract

Apparatus and a method for detecting electromagnetic radiation emitted by a device, the device including multiple components that emit electromagnetic radiation. The apparatus comprises a container lined with electromagnetic anechoic absorber, a support located within the container for receiving the device, a planar antenna located within the container for detecting electromagnetic radiation emitted by the device, the antenna being movable relative to the support to vary the distance between the antenna and the support,and measurement apparatus for recording the electromagnetic radiation emitted by the device at different positions of the antenna relative to the support.

IPC Classes  ?

• G01R 29/08 - Measuring electromagnetic field characteristics

Abstract

The invention relates to novel and known substituted phosphonates for use in ameliorating amyloid aggregates, particularly for use in the treatment of Alzheimer's disease.

IPC Classes  ?

• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07F 9/40 - Esters thereof
• C07F 9/572 - Five-membered rings
• C07F 9/60 - Quinoline or hydrogenated quinoline ring systems
• C07F 9/64 - Acridine or hydrogenated acridine ring systems
• C07F 9/6506 - Five-membered rings having the nitrogen atoms in positions 1 and 3
• C07F 9/653 - Five-membered rings
• C07F 9/655 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
• C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• A61K 31/665 - Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Abstract

The present invention provides histone deacetylase inhibitors of general formula (I), a process for the preparation of such compounds and uses of the compounds in medicine, especially in the treatment of cancers: in which R1 is an optionally substituted aryl, arylalkyl, heteroaryl, heterocycloalkenyl, cycloalkene ring, cycloalkyl, heterocycloalkyl or a combination of such rings to form a linked or fused ring system, R2 and R3 is each independently hydrogen, optionally substituted saturated or unsaturated alkyl, optionally substituted aryl or heteroaryl, or a combination thereof to form a linked or fused ring system, alkoxy, thioalkoxy, hydroxyl, hydroxyalkyl, halo, haloalkyl, cyano, nitro, amino, amido, alkylamino, alkylcarbonyloxy, alkoxycarbonyl, alkylcarbonyl, alkylthiocarbonyl, alkylsulfonylamino, aminosulfonyl, alkylsulfinyl, or alkylsulfonyl, or R3 is absent when Y stands for O or S, or R2 and R3 may be linked together and such that, together with the intervening atoms, they form a 5, 6 or 7-membered ring containing one or more heteroatoms, which may be a heteroaryl ring, heterocycloalkenyl ring, or heterocycloalkyl ring, optionally containing up to 4 heteroatoms, e.g. oxygen, nitrogen or sulphur, which ring may be fused to further rings as part of a fused ring system, and which may bear 1, 2 or 3 substituents, which substituents independently have the same meaning as R2 on any or all of those rings, Q stands for an (alkyl, which may be unsaturated; aryl, arylalkyl, alkylaryl or alkylarylalkyl, all of which may be optionally substituted; and may be optionally interrupted by O, S, NR, CO, C(N=R), where R may be independently hydrogen, alkyl, alkenyl, alkynyl, or alkoxy; V is OH, SH, SR, OR, NH2, NHR, NRR, NROH, NHOR, NROR where R may independently be hydrogen or (C1-C6) alkyl, Y is oxygen, or sulphur or N, and Z is O, S, S(=O), S(O)2, NR4, -N=, CR4R5, or -C(R4)=, where R4 and R5 independently have the same meaning as R2.

IPC Classes  ?

• C07D 285/08 - 1,2,4-ThiadiazolesHydrogenated 1,2,4-thiadiazoles

Abstract

Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6813 - Hybridisation assays
• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation

Abstract

Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G06G 7/58 - Analogue computers for specific processes, systems, or devices, e.g. simulators for chemical processes